GERN
GERON CORP
NASDAQ · Healthcare · Biotechnology · US
$1.04
+11.29%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.00
From 52W high−46.92%
Volume19.46M
Market cap$664.96M
P/E (TTM)—
P/S (TTM)3.3x
Div yield—
Key dataNov 4, 2026
Open
$1.00
From 52W high
−46.92%
Volume
19.46M
Market cap
$664.96M
ValuationView details →
P/E (Fwd)
22.5x
EV/EBITDA
−11.8x
P/E (TTM)
—
RSI (14)
36.7
MomentumView details →
1D Return
+11.29%
YTD Return
−24.62%
SummaryUpdated Jun 1, 2026
Geron Corporation (NASDAQ:GERN) is a late-stage clinical biopharmaceutical company founded in 1990 and headquartered in Foster City, California. The company went public in 1996 and has focused its efforts on developing therapeutics for blood cancers, specifically myeloid hematologic malignancies. After decades of research and development, Geron achieved a significant milestone in June 2024 with the FDA approval of its lead drug candidate, imetelstat, which is now marketed under the brand name <b>RYTELO</b>. The company has transitioned from a purely clinical-stage entity to a commercial organization with its first approved product generating revenue.
Similar companies
Latest newsMore news →
GERON CORP reported break-even earnings per share for the third quarter, compared with a loss of $0.03 per share a year earlier.5h agoGERON CORP announced that six abstracts on RYTELO (imetelstat) were accepted for poster presentation at the 68th American Society of Hematology Annual Meeting.6h agoGERON CORP announced two oral presentations and one poster presentation on imetelstat in patients with lower-risk myelodysplastic syndromes at hematology meetings in Japan and the German-speaking region.23d ago